PREDIABET BEMORLARDA XAVFNI STRATIFIKATSIYA QILISH UCHUN ZARDOBDAGI SISTATIN C
Abstrakt
Tadqiqot maqsadi xavf tabaqalanishi uchun prediabetli bemorlar orasida Sistatin-C qiymatini o‘rganish. Materiallar va tadqiqot usullari. Tadqiqotimiz 18 yoshdan 65 yoshgacha bo‘lgan 55 kishini, shu jumladan o‘rtacha yoshi 54,3±3,2 yosh bo‘lgan 35 erkak va o‘rtacha yoshi 51,1±2,1 yosh bo‘lgan 20 nafar ayolni o‘z ichiga oldi. O‘rganish Andijon viloyat endokrinologiya dispanserida o‘tkazildi. Nazorat guruhi 20 nafar sog'lom odamdan iborat edi. Tadqiqot usullari: umumiy klinik usullar, biokimyoviy tahlillar (qondagi glyukoza darajasi va ovqatdan keyin 2 soat o‘tgach, glyukozalangan gemoglobin, bilirubin, to‘g'ridan-to‘g'ri va bilvosita, ALT, AST, PTI, koagulogramma, C-reaktiv oqsil, karbamid, kreatinin, lipid spektri, zarur bo‘lgan insulin-C darajasi, sistatin-S), gormonal tadqiqotlar. qon) va instrumental usullar: EKG, endokrin bezlar va ichki organlarning ultratovush tekshiruvi, ko‘krak qafasi rentgenogrammasi va boshqalar. Tadqiqot natijalari. Prediabet ASYuE (prediabet: CI: 1,08-1,15; P <0,001), surunkali buyrak kasalligi (prediabet: CI: 1,02-1,14; P <0,001; ) va yurak etishmovchiligi (prediabet: CI: 1,01;P = 1.0) uchun xavf omilidir. Gemoglobin A1c (HbA1c) darajasi 5,0% dan kam bo‘lgan gemoglobin A1c (HbA1c) darajasi bilan solishtirganda, HbA1c 5,4% dan yuqori bo‘lgan ASYeE, surunkali buyrak kasalligi 6,2% va yurak etishmovchiligi 7,0 dan yuqori bo‘lgan kovariatlarga moslashtirilgan xavflar sezilarli darajada oshdi. Xuddi shu tarzda, CRCning o‘rtacha qiymatlari boshqaruv guruhiga nisbatan ishonchli o‘sdi ((p <0.005) bilan taqqoslangan. Shuni ta'kidlash kerakki, barcha guruhlarda ruxsat etilgan chegaralarida ular nazoratdan sezilarli darajada farq qilar ekan. Xulosa. Qandli diabet chegarasidan pastroq bo‘lgan HbA 1c darajalarida xavf gradienti kuzatildi. Ushbu natijalar glisemik spektr bo‘ylab xavfni kamaytirish strategiyalarini ishlab chiqish zarurligini ta'kidlaydi. Sistatin C darajasining ko‘tarilishi, kreatinin kabi boshqa belgilar hali sezilarli darajada o‘zgarmagan bo‘lsa ham, CKDni dastlabki bosqichlarda ham aniqlashi mumkin.
Nashr sanasi
Mualliflar haqida
Adabiyotlar ro'yxati
Vart P. et al. National trends in the prevalence of chronic kidney disease among racial/ethnic and socioeconomic status groups, 1988-2016 //JAMA network open. – 2020. – Т. 3. – №. 7. – С. e207932-e207932.
Plantinga L. C. et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes //Clinical Journal of the American Society of Nephrology. – 2010. – Т. 5. – №. 4. – С. 673-682.
Kidney G. Disease: Improving Global Outcomes Diabetes Work,“KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease” //Kidney Int. – 2022. – Т. 102. – С. S1-S127.
American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes—2021 //Diabetes Care. – 2021. – Т. 44. – №. Supplement_1. – С. S85-S99.
Sallar A., Dagogo-Jack S. Regression from prediabetes to normal glucose regulation: state of the science //Experimental Biology and Medicine. – 2020. – Т. 245. – №. 10. – С. 889-896.
Kalaitzidis R. G., Bakris G. L. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? //Current opinion in nephrology and hypertension. – 2009. – Т. 18. – №. 5. – С. 386-391.
Kim H. J. et al. Clinical features and predictors of masked uncontrolled hypertension from the Korean Ambulatory Blood Pressure Monitoring Registry //The Korean Journal of Internal Medicine. – 2021. – Т. 36. – №. 5. – С. 1102.
Honigberg MC, Zekavat SM, Pirruccello JP, Natarajan P, Vaduganathan M. Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank. //J Am Coll Cardiol. 2021 Aug 3;78(5):453-464. doi: 10.1016/j.jacc.2021.05.004.
Xiong K, Zhang S, Zhong P, Zhu Z, Chen Y, Huang W, Wang W. Serum cystatin C for risk stratification of prediabetes and diabetes populations. //Diabetes Metab Syndr. 2023 Nov;17(11):102882. doi: 10.1016/j.dsx.2023.102882
Sabanayagam C, Wong TY, Xiao J, Shankar A. Serum cystatin C and prediabetes in non-obese US adults. //Eur J Epidemiol. 2013 Apr;28(4):311-6. doi: 10.1007/s10654-013-9781-3
Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, Palmas W, Siscovick D, Levey AS, Shlipak MG. Cystatin C identifies chronic kidney disease patients at higher risk for complications.// J Am Soc Nephrol. 2011 Jan;22(1):147-55. doi: 10.1681/ASN.2010050483.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.